Sign inJoin waitlistJoin the waitlist

Jacqueline Garcia

Associate Professor of Medicine, Harvard Medical School · Mass General Brigham

Credentials: · · · · · · ·

History

Mass General Brigham
Present

Stanford University
2011–2014
Internal Medicine
University of Chicago Medical Center
2008–2011
University of Illinois College of Medicine
2004–2008

Research

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine · 2020 · 2,437 citations
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
American Journal of Hematology · 2024 · 216 citations
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Cancer Cell · 2016 · 216 citations

Richard Stone
37 papers
Daniel DeAngelo
34 papers
Marlise Luskin
32 papers
Eric Winer
26 papers
Evan Chen
19 papers · 5 as a fellow
Martha Wadleigh
19 papers
Shai Shimony
15 papers
Coleman Lindsley
14 papers
AL
Anthony Letai
13 papers
Maximilian Stahl
13 papers
Robert Soiffer
13 papers
IG
Ilene Galinsky
12 papers

Grants

Prospective Dynamic BH3 Profiling for Clinical Use in Relapsed or Refractory AML
National Cancer Institute · R37
Contact PI · $388.6K · Dana-Farber Cancer Inst
2026–2031
Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
National Cancer Institute · K08
Contact PI · $1.3M · Dana-Farber Cancer Inst
2020–2025

Clinical trials

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
Jacqueline Garcia, MD
2026–2029
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Principal investigator · Recruiting · Phase 1, Phase 2
Jacqueline Garcia, MD
2026–2030
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Principal investigator · Active not recruiting · Phase 1
Jacqueline Garcia, MD
2022–2026
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2019–2027